MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Core Viewpoint - MannKind Corporation is set to release its 2024 fourth quarter and full year financial results on February 26, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be discussed in a webcast starting at 4:30 p.m. Eastern Time, featuring CEO Michael Castagna and CFO Chris Prentiss [2] - The webcast will be accessible on MannKind's investor relations website, with a replay available for approximately 90 days [2] Group 2: Company Overview - MannKind Corporation focuses on developing and commercializing innovative inhaled therapeutic products for serious unmet medical needs, particularly in endocrine and orphan lung diseases [3] - The company aims to alleviate the burden of diseases such as diabetes, NTM lung disease, pulmonary fibrosis, and pulmonary hypertension through its advanced formulation and device engineering capabilities [4] - MannKind's technologies include dry-powder formulations and inhalation devices that enable rapid and convenient delivery of medications to the lungs [4]